#tenofovir disoproxil fumarate

Two men claim they developed bone and kidney problems after taking TDF. A related class action lawsuit has also been filed.

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.

Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.

People with HIV taking Viread, especially if combined with Norvir, should receive regular kidney monitoring.

The Food and Drug Administration recently approved a generic formulation of Gilead Sciences’ antiretroviral Truvada.

Although more research on antiretroviral linked bone loss is needed, the overall health benefits of early treatment outweigh such a risk.

A recent study stresses the importance of osteoporosis screening for HIV-positive men older than 50.

Researchers have made progress in developing a microbicide enema that protects against contracting HIV through anal sex.

New trial compares Descovy to Truvada.

Koen Van Rompay hopes to stop mother-to-child transmission of Zika virus, just like he did with HIV.

The AIDS Healthcare Foundation alleges Gilead could have developed the safer version of tenofovir earlier.

Increases may be designed to push patients to the company’s newer regimens.

Among people who fail HIV treatment, resistance to tenofovir is common, and the incidence of such acquired resistance is likely increasing.

Gilead Sciences has filed for approval of Truvada as pre-exposure prophylaxis (PrEP) against HIV with the European Medicines Agency.

Lawsuit: Gilead has manipulated the patent system to extend its control (and profit) of tenofovir, found in many HIV regimens.